NCT00969540

Brief Summary

Sleep quantity and quality can be influenced by the type of mattress used. This study is being done to see if a mattress cover with optically active particles can help back pain and improve sleep quality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2009

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 31, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 1, 2009

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
3.4 years until next milestone

Results Posted

Study results publicly available

December 3, 2014

Completed
Last Updated

December 3, 2014

Status Verified

December 1, 2014

Enrollment Period

2.1 years

First QC Date

August 31, 2009

Results QC Date

June 29, 2012

Last Update Submit

December 2, 2014

Conditions

Keywords

Back PainSleep

Outcome Measures

Primary Outcomes (1)

  • Optically Modified Polyethylene Terephthalate Fiber Mattress Cover (OMPETFMC) Improves Sleep Quality in Patients With Lower Back Pain as Measured by Clinical Global Impression (CGI).

    The primary outcomes are the change in mean daily Clinical Global Impressions (pain and sleep) in placebo mattress compared to active mattress cover (assessed daily for 14 days per intervention). The daily scores range from 1 (very much improved) to 7 (very much worse).

    14 days

Secondary Outcomes (5)

  • Sleep Variables (Nighttime Wake-time) Measured With Actigraphy in Patients With Lower Back Pain.

    Assessed daily for 14 days per intervention.

  • Sleep Variables (Total Sleep) Measured With Actigraphy in Patients With Lower Back Pain.

    Assessed daily for 14 days per intervention.

  • Sleep Variables (Nocturnal Awakenings) Measured With Actigraphy in Patients With Lower Back Pain.

    Assessed daily for 14 days per intervention.

  • Sleep Variables (Sleep Efficiency) Measured With Actigraphy in Patients With Lower Back Pain.

    Assessed daily for 14 days per intervention.

  • Sleep Variables (Sleep Latency) Measured With Actigraphy in Patients With Lower Back Pain.

    Assessed daily for 14 days per intervention.

Study Arms (2)

Active Mattress Cover

ACTIVE COMPARATOR

Subjects in this arm will be given the placebo mattress cover followed active mattress cover .

Device: Active Mattress Cover

Placebo Mattress Cover

PLACEBO COMPARATOR

Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.

Device: Placebo Mattress Cover

Interventions

Active Mattress Cover

Active Mattress Cover

Placebo Mattress Cover

Placebo Mattress Cover

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • You are eligible to participate in this study if you:
  • have a clinical diagnosis of chronic lower back pain
  • have pain measured on the Visual Analogue scale
  • have sleep disturbances at night associated with chronic lower back pain
  • are 18 years or older
  • sign the written, informed consent form prior to the initiation of any study procedures
  • have an habitual bedtime between 8 P.M. and 12 A.M.
  • are on a stable pain management regime

You may not qualify if:

  • You are not eligible to participate in this study if you:
  • are unwilling or unable to comply with the protocol or scheduled appointments
  • are unable to understand the language in which the approved informed consent is written
  • have no pain measured on the Visual Analogue scale
  • are unable to walk, wheel chair bound or confined to bed
  • are deemed by the investigator to be unreliable to wear the actigraphy, to complete the sleep log, to use the provided mattress covers at the proper time, to come to the scheduled visits or to answer questions regarding the subject's condition or medication use
  • lack a mobile arm to which to attach an actigraphy.
  • are currently participate or participated in another clinical study within the past 30 days
  • demonstrate an unwillingness to comply with the maximum limit of two alcoholic drinks per day and only 1 alcoholic drink after 6:00 P.M. for the duration of the protocol
  • use tobacco products or any other products during nightly awakenings that may interfere with the sleep wake cycle
  • have any unstable medical condition as determined by the investigator, or any other serious disease or condition that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UC Irvine-MDA ALS and Neuromuscular Center

Orange, California, 92868, United States

Location

MeSH Terms

Conditions

Back PainSleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Limitations and Caveats

This is a pilot study to determine the framework to study sleep, pain and mattress covers. The number of subjects is small. The observed data is evaluated in a descriptive (bar graph) presentation.

Results Point of Contact

Title
Seth Casden
Organization
Hologenix, LLC

Study Officials

  • Annabel K Wang, MD

    UC Irvine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Clinical Professor

Study Record Dates

First Submitted

August 31, 2009

First Posted

September 1, 2009

Study Start

June 1, 2009

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

December 3, 2014

Results First Posted

December 3, 2014

Record last verified: 2014-12

Locations